Moderna's Flu Vaccine Outperforms Standard Shot in Trial

Moderna's experimental flu vaccine has beaten the standard flu shot in a massive clinical trial, offering fresh hope that the mRNA technology behind COVID vaccines could soon deliver better protection during flu season.

The company's mRNA-1010 vaccine showed 26.6% stronger protection than traditional flu shots in adults over 50, according to Phase 3 trial results published in the New England Journal of Medicine. More than 40,000 adults participated in the study, and regulators in the United States, Europe, Canada, and Australia are now reviewing the data for potential approval later this year.

The results mark a significant step forward for Moderna as it works to prove its platform can tackle more than just COVID-19. Unlike traditional flu vaccines that grow viruses in chicken eggs, mRNA vaccines use genetic instructions to teach cells how to fight infection. This approach could allow faster updates when flu strains change and potentially stronger immune responses in older adults who need protection most.

Beyond flu, Moderna is also advancing an mRNA vaccine for hantavirus in partnership with Korea University's Vaccine Innovation Center. The collaboration aims to address emerging infectious diseases that don't always attract attention from traditional vaccine makers. While the hantavirus program still needs funding to start human trials, it shows how mRNA technology could respond quickly to future outbreaks.

The Ripple Effect

If approved, mRNA-1010 would enter a massive seasonal market currently dominated by Sanofi, GSK, and Pfizer. But this isn't just about competition. Better flu vaccines could prevent thousands of hospitalizations and deaths each year, especially among older adults and people with weakened immune systems who respond poorly to current options.

The technology's flexibility matters too. When dangerous flu strains emerge, mRNA vaccines can be redesigned in weeks rather than months. That speed could prove crucial during severe flu seasons or future pandemics.

Moderna's stock jumped 10% on the news, reflecting investor optimism that the company is finally diversifying beyond COVID vaccines. The timing matters for a business that has seen its fortunes swing wildly, from pandemic hero to struggling to maintain relevance as COVID concerns fade.

For the millions who get flu shots each year, the choice may soon include an option built on technology that has already protected billions worldwide.